SCHEMBL23770833

SCHEMBL23770833

COc1ccc(Cl)c(-c2nc(N[S+]([O-])c3cccc(N4CCNCC4)n3)ccc2C(F)(F)F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.39
HTR3A P46098 3/20 0.34
CYP1A2 P05177 2/20 0.34
HTR3E A5X5Y0 1/20 0.34
HTR3B O95264 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HTR3D Q70Z44 1/20 0.34
HTR3C Q8WXA8 1/20 0.34
CYP2C9 P11712 1/20 0.34
ADRB1 P08588 1/20 0.33
PHGDH O43175 1/20 0.33
PLA2G7 Q13093 1/20 0.33
SOS1 Q07889 1/20 0.33
HTR1A P08908 3/20 0.33
CHEK1 O14757 1/20 0.32
ALK Q9UM73 1/20 0.32
MAPK10 P53779 1/20 0.32
CYP2C19 P33261 1/20 0.32
PIM1 P11309 1/20 0.32
SUV39H2 Q9H5I1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770733 0.88 PDE10A (0.32) PHGDHMAPK10HSD17B10
SCHEMBL23770598 0.87 ADRB2 (0.43) ADRB2HTR3ACYP1A2HTR3EHTR3B
SCHEMBL23770477 0.86 MAPK10 (0.36) CYP1A2PHGDHMAPK10HSD17B10HTR2C
SCHEMBL19925629 0.81 ADRB2 (0.39) ADRB2HTR3ACYP1A2HTR3EHTR3B
SCHEMBL23770643 0.81 ADRB2 (0.37) ADRB2HTR3ACYP1A2HTR3EHTR3B
Hydrochloric Acid SCHEMBL19925392 0.81 ADRB2 (0.40) ADRB2HTR3ACYP1A2HTR3EHTR3B
SCHEMBL23770622 0.78 CTSL (0.36) ADRB2HTR3AHTR3EHTR3BALDH1A1
SCHEMBL23770816 0.78 PDE10A (0.35) ALK
SCHEMBL23770441 0.78 HTR3E (0.43) HTR3ACYP1A2HTR3EHTR3BALDH1A1
SCHEMBL23770812 0.74 HSD11B1 (0.30) SOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed